Drug Approval | June 05, 2025
UK MHRA approves aumolertinib to treat non-small cell lung cancer
Aumolertinib can be used in patients who have tested positive for a mutation in a gene called epidermal growth factor receptor
Aumolertinib can be used in patients who have tested positive for a mutation in a gene called epidermal growth factor receptor
Newly commissioned MCC in Jhagadia and Dahej and CCS project expansions will unlock an additional 8,800 MTPA, fuelling year-over-year revenue gains of 20%-30% in excipients
Pivotal results from the Phase 3 Breakwater trial showed 51% risk reduction in death compared to standard-of-care treatment
The company also announced results for the third quarter, reporting sales at Rs. 992 crore, flat versus year ago
The decision to withdraw the BLA is based on topline overall survival (OS) results from the confirmatory HERTHENA-Lung02 Phase 3 trial where OS did not meet statistical significance
Usnoflast has previously also received ‘Orphan Drug Designation (ODD)’ from the USFDA
Akums invested Rs. 272 crore in capital expenditure during FY25
R&D spend for Q4 was Rs. 50.3 crore, 4.9 per cent of Q4?revenue
Sun Pharma will invest up to $25 million in US-based Pharmazz Inc, raising its stake to 22.7%
3SBio will receive an upfront payment of $1.25 billion and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8 billion
Subscribe To Our Newsletter & Stay Updated
